Abbreviations: MLS = myxoid liposarcoma; MYX = myxoid; RC = round

Abbreviations: MLS = myxoid liposarcoma; MYX = myxoid; RC = round cell; wt = wild type; mut = mutated; DDIT3 split = FISH probe indicates interrupted gene; na = not available; nd = not determinable. Additional file 1: Table S3. Soft tissue sarcoma cell lines. Cell line name, tissue of origin (soft tissue sarcoma subtype), molecular confirmation, culture conditions

and source/reference is given for each cell line tested for TERT promoter mutations. 17-AAG in vitro Abbreviations: FCS = fetal calf serum; PS = penicillin and streptomycin; PMID = PubMed identifier. (XLSX 42 KB) References 1. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F: WHO Classification of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2013. 2. Goldblum JR, Folpe AL, Weiss SW: General Considerations. In In Enzinger and Weiss’s Soft Tissue Tumors. 6th edition. Edited by: Enzinger and Weiss’s Soft Tissue Tumors. City: Mosby; 2013:1–10. [Book General Considerations] 3. Stojadinovic A, Yeh A, Brennan MF: Completely resected recurrent soft tissue sarcoma: primary anatomic site governs outcomes. J Am Coll Surg 2002, 194:436–447.PubMedCrossRef 4. Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer click here S, Ladanyi M: Advances in sarcoma genomics and new therapeutic targets.

Nat Rev Cancer 2011, 11:541–557.PubMedCentralPubMedCrossRef 5. Renner M, Wolf T, Meyer H, Hartmann W, Penzel R, Ulrich A, Lehner B, Hovestadt V, Czwan E, Egerer G, Schmitt T, Alldinger I, Renker

EK, Ehemann V, Eils R, Wardelmann E, Buttner R, Lichter either P, Brors B, Schirmacher P, Mechtersheimer G: Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas. Genome Biol 2013, 14:r137.PubMedCrossRef 6. van de Rijn M, Fletcher JA: Genetics of soft tissue tumors. Annu Rev Pathol 2006, 1:435–466.PubMedCrossRef 7. Xu L, Li S, Stohr BA: The role of telomere biology in cancer. Annu Rev Pathol 2013, 8:49–78.PubMedCrossRef 8. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011–2015.PubMedCrossRef 9. Kyo S, Takakura M, Fujiwara T, Inoue M: Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human AC220 cancers. Cancer Sci 2008, 99:1528–1538.PubMedCrossRef 10. Heidenreich B, Rachakonda PS, Hemminki K, Kumar R: TERT promoter mutations in cancer development. Curr Opin Genet Dev 2014, 24:30–37.CrossRef 11. Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R: TERT promoter mutations in familial and sporadic melanoma. Science 2013, 339:959–961.PubMedCrossRef 12.

Related posts:

1. J Exp Clin Cancer Res 2012, 31:1756–9966 13 Zhou SL, Cui J, Fan
2. The presence of activating mutations in the tyrosine kinase
3. PubMedCrossRef 15 Turashvili G, Bouchal J, Burkadze G, Kolar Z:
4. The expression
   
   level of DKK-1, an inhibitor of canonical
5. PubMedCrossRef 3 Portela A, Esteller M: Epigenetic modifications